Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Randomized Clinical Trials Using New Technologies in Radiation Oncology Ethical Dilemma for Medicine and Science

Randomized Clinical Trials Using New Technologies in Radiation Oncology Ethical Dilemma for... EDITORIAL Randomized Clinical Trials Using New Technologies in Radiation Oncology Ethical Dilemma for Medicine and Science Rafal Dziadziuszko, MD, PhD, and Jacek Jassem, MD, PhD n this issue of the Journal of Thoracic Oncology, Dr. Roelofs et al. present the results Iof multicenter comparative planning study of 25 consecutive stage I–IIIA non-small cell lung cancer (NSCLC) patients with the use of three-dimensional conformal photon (3DCRT), intensity modulated photon (IMRT), and passive scattered proton radiotherapy (ROCOCO study). The patients were scanned with four-dimensional 18F-fluorodeoxy- glucose-positron emission tomography/computed tomography and targets were delineated at the Department of Radiation Oncology, Maastricht University. Subsequently, partici- pating centers used their own treatment planning systems according to predefined criteria and reported their plans through a centralized database. The results are shown according to two scenarios—with prescribed dose of 70 Gy in 35 fractions to planning target volume and by adapting the fraction dose to fulfill the toxicity criteria for organs at risk (isotoxic dose escalation per fraction). This and other in silico trials in radiotherapy raise several important issues. Rapid technological progress in diagnostic and therapeutic use of radiation allows for more accurate treatment planning and higher dose delivery to the tumor. This often leads http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Randomized Clinical Trials Using New Technologies in Radiation Oncology Ethical Dilemma for Medicine and Science

Jassem, Jacek
Journal of Thoracic Oncology , Volume 7 (1) – Jan 1, 2012
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/randomized-clinical-trials-using-new-technologies-in-radiation-CV7wOxgYf6

References (4)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31823c5a4e
pmid
22173658
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Randomized Clinical Trials Using New Technologies in Radiation Oncology Ethical Dilemma for Medicine and Science Rafal Dziadziuszko, MD, PhD, and Jacek Jassem, MD, PhD n this issue of the Journal of Thoracic Oncology, Dr. Roelofs et al. present the results Iof multicenter comparative planning study of 25 consecutive stage I–IIIA non-small cell lung cancer (NSCLC) patients with the use of three-dimensional conformal photon (3DCRT), intensity modulated photon (IMRT), and passive scattered proton radiotherapy (ROCOCO study). The patients were scanned with four-dimensional 18F-fluorodeoxy- glucose-positron emission tomography/computed tomography and targets were delineated at the Department of Radiation Oncology, Maastricht University. Subsequently, partici- pating centers used their own treatment planning systems according to predefined criteria and reported their plans through a centralized database. The results are shown according to two scenarios—with prescribed dose of 70 Gy in 35 fractions to planning target volume and by adapting the fraction dose to fulfill the toxicity criteria for organs at risk (isotoxic dose escalation per fraction). This and other in silico trials in radiotherapy raise several important issues. Rapid technological progress in diagnostic and therapeutic use of radiation allows for more accurate treatment planning and higher dose delivery to the tumor. This often leads

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2012

There are no references for this article.